QurientPress Release


 

Press Release

  • 160
    • 큐리언트, MD앤더슨과 아드릭세티닙 병용임상 개시

      혁신 신약 개발 전문기업인 큐리언트(115180)는 아드릭세티닙(Adrixetinib, Q702)의 급성 골수성 백혈병(AML) 임상시험이 개시되었다고 25일 밝혔다. 이번 임상시험은 지난 6월 IND 승인을 받은 MD 앤더슨 암센터(MD Anderson Cancer Center) 주관의 임상시험으로, 재발성/불응성 급성....Article Source : 메디파나뉴스
      Link : https://www.medipana.com/article/view.php?news_idx=332890&sch_cate=D

      Date
      2024-10-25
      Author
      QURIENT
  • 159
  • 158
  • 157
  • 156
  • 155
  • 154
  • 153
  • 152
  • 151
    • Qurient Therapeutics Enters CRADA with the National Cancer I…

      Article Source : BusinessWire
      Link : https://www.businesswire.com/news/home/20240521344307/en/Qurient-Therapeutics-Enters-CRADA-with-the-National-Cancer-Institute-to-Collaborate-on-a-Phase-12-Clinical-Study-of-Q901-in-Combination-with-TROP2-ADC

      Date
      2024-05-21
      Author
      QURIENT
  • 150
  • 149
  • 148
  • 147
  • information for download file